Aquinox Pharmaceuticals Inc (AQXP) : Nexthera Capital Lp reduced its stake in Aquinox Pharmaceuticals Inc by 31.77% during the most recent quarter end. The investment management company now holds a total of 340,000 shares of Aquinox Pharmaceuticals Inc which is valued at $4,831,400 after selling 158,300 shares in Aquinox Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Aquinox Pharmaceuticals Inc makes up approximately 3.80% of Nexthera Capital Lp’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in AQXP in the latest quarter, The investment management firm added 20,570 additional shares and now holds a total of 83,519 shares of Aquinox Pharmaceuticals Inc which is valued at $1,081,571.Blackrock Investment Management boosted its stake in AQXP in the latest quarter, The investment management firm added 4,858 additional shares and now holds a total of 25,358 shares of Aquinox Pharmaceuticals Inc which is valued at $279,952.Blackrock Institutional Trust Company N.a. boosted its stake in AQXP in the latest quarter, The investment management firm added 20,414 additional shares and now holds a total of 220,071 shares of Aquinox Pharmaceuticals Inc which is valued at $2,429,584. Td Asset Management Inc added AQXP to its portfolio by purchasing 78,707 company shares during the most recent quarter which is valued at $817,766.
Aquinox Pharmaceuticals Inc closed down -0.025 points or -0.17% at $14.63 with 1,89,952 shares getting traded on Monday. Post opening the session at $14.82, the shares hit an intraday low of $14.18 and an intraday high of $15.0443 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Aquinox Pharmaceuticals Inc. Leerink Partners Resumed Aquinox Pharmaceuticals Inc on Oct 4, 2016 to “Outperform”, Price Target of the shares are set at $24.
Aquinox Pharmaceuticals Inc. formerly Aquinox Pharmaceuticals (USA) Inc. is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1 which is a regulator of a cellular signaling pathway in immune cells known as the PI3K pathway. Its lead product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125 it is advancing through Phase II development in several initial indications. The Company operates in Vancouver British Columbia Canada.